Approval is based on ODYSSEY OUTCOMES trial of 18,924 patients who recently suffered an acute coronary syndrome such as a heart attack Praluent is the only EU-approved PCSK9 inhibitor with ...

TARRYTOWN, N.Y. and PARIS, Feb. 4, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products ...

SAN DIEGO—Sanofi and Regeneron still have months to wait for final data from a key cardiovascular outcomes study of their PCSK9 therapy Praluent. But the pair now has results in hand suggesting the ...

In 4Q15, Sanofi earned $7 million from Praluent. The drug received approval in the US in July 2015 and earned $11 million in fiscal 2015. Regeneron Pharmaceuticals (REGN) co-markets the drug with ...

A U.S. federal judge has issued an injunction against U.S. sales of Sanofi and Regeneron's Praluent in a patent fight. A U.S. federal judge handed Sanofi and partner Regeneron a stunning loss with a ...

Sanofi and Regeneron’s Praluent may still not be cost effective compared to other cholesterol-lowering drugs despite a recent price cut, a new study has claimed. The drug's high price point has long ...

(Reuters) - Regeneron Pharmaceuticals Inc and Sanofi SA said on Saturday they would be willing to charge less for their potent cholesterol drug, Praluent, if insurers agree to lessen onerous access ...

New results on alirocumab (Praluent) show that it is safe and effective for patients with familial hypercholesterolemia (FH), and yet these patients are faced with an unprecedented situation where ...

The ruling means that barring a settlement or a reversal on appeal, Sanofi and Regeneron could be forced to stop selling Praluent within 6 weeks. A federal judge said Monday that Sanofi and Regeneron ...

The FDA approved Amgen's (AMGN) cholesterol drug Repatha late Thursday, giving it a similar label to a recently approved rival from Regeneron (REGN) and Sanofi (SNY), but a slightly lower price. The ...